Zealand Pharma A/S

Good day and thank you for standing by. Welcome to the Zealand Pharma results for full year 2023 webcast. At this time all participants are in a listen only mode. After the speaker's presentation there will be a question and answer session. To ask a question during the session you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Anna Krasowska, VP of Investor Relations. Please go ahead.

Thank you, Operator. Welcome and thank you for joining us today to discuss VLANs results for the full year of 2023. With me today are the following members of VLANs management team. Adam Steinsberg, President and Chief Executive Officer, Henrietta Winnecke, Chief Financial Officer, and David Kendall, Chief Medical Officer. You can also find the related company announcement and annual report on our website at zeelandpharma.com. As described on slide two, I caution listeners that we will be making forward-looking statements that are subject to risks and uncertainties. Moving to slide three, I will turn the call over to Adam Steinsberg, President and CEO. Adam?

Thank you, Anna, and thanks for everyone for joining today. 2023 was an extraordinary year for Sealand. I'm very proud of our team's performance to deliver significant progress across our obesity and rare disease assets while building a strengthened financial position. In obesity, we reported positive phase one results for proctrinatide that support our conviction for amylin's potential as a monotherapy and an alternative to the GLP-1-based therapies. With dabiglutide, we have a truly differentiated GLP-1-containing molecule, and we are very excited about the trials evaluating its potential to address not only obesity, but also low-grade inflammation associated with metabolic diseases. Our partner Boehringer reported Phase 2 results for servolutide in obesity and advanced the molecule into a global phase 3 program. And yesterday's top line results in mass provide evidence of clear differentiation that potentially positions servolutide to become a leading GLP-1 containing weight loss medication. And finally, with two NDA submissions, we progressed our rare disease products into the regulatory phase towards patients who need them. Moving to slide four, CELAN is well positioned to achieve significant milestones in 2024. We look forward to important clinical results for both of our wholly owned and differentiated obesity assets that we anticipate will position us to expand our efforts and advance into substantial phase 2b trials. We will work closely with the FDA during the NDA review of our two rare disease assets, dasigluargon in congenital hyperinsulinism and glipaglutide in short bowel syndrome. For these assets, we also expect to progress our partnership discussions further. This year, we also expect two of our preclinical programs targeting inflammation to move into first in human trials. Moving to slide five, I will now turn over the call to our CMO, David Kendall, to discuss our R&D pipeline. David.